Grail

Grail Book Value per Share

The Book Value per Share of Grail (GRAL) as of Oct 15, 2026 is 66.13 USD. In the previous year, Book Value per Share was 64.22 USD — a change of 2.97% (higher).

Book Value per Share

66.13USD

YoY

2.97%

Last updated:

Book Value per Share of Grail is 2025 66.13 USD. Book Value per Share of Grail was 2024 64.22 USD. It decreases by 2.97% higher compared to the previous year.

The Grail Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
15.40 USD
Jan 1, 2019
14.12 USD
Jan 1, 2020
14.41 USD
Jan 1, 2021
241.93 USD
Jan 1, 2022
119.19 USD
Jan 1, 2023
93.54 USD
Jan 1, 2024
64.22 USD
Jan 1, 2025
66.13 USD
The Grail Book Value per Share history
YEARBook Value per ShareYoY
66.13USD+2.97%
64.22USD-31.34%
93.54USD-21.52%
119.19USD-50.73%
241.93USD+1,578.52%
14.41USD+2.05%
14.12USD-8.30%
15.40USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grail stock

Book Value per Share of Grail is 66.13 USD in 2025.

Book Value per Share of Grail changed from 64.22 USD to 66.13 USD, representing a 2.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Grail since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Grail

All Key Metrics — Grail